The present invention provides a compound of formula (I):
wherein:
• R1 is a group selected from -CH2OH, -NHC(O)H and
• R2 is a hydrogen atom; or
• R1 together with R2 form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R2
• R3 is selected from hydrogen and halogen atoms or groups selected from -SO-R5, -SO2-R5, -NH-CO-NH2, -CO-NH2, hydantoino, C1-4alkyl, C1-4alkoxy and -SO2NR5R6
• R4 is selected from hydrogen atoms, halogen atoms and C1-4alkyl groups
• R5 is a C1-4alkyl group or C3-8 cycloalkyl
• R6 is independently selected from hydrogen atoms and C1-4alkyl groups
• n, p and q are independently 0, 1, 2, 3 or 4
• m and s are independently 0, 1, 2 or 3
• r is 0, 1 or 2
with the provisos that:
• at least one of m and r is not 0
• the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13
• the sum q+r+s is 2, 3, 4, 5 or 6
or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.
本发明提供了一种式 (I) 的化合物:
其中
- R1 是选自-CH2OH、-NHC(O)H 的基团,以及
- R2 是氢原子;或
- R1与R2一起形成基团-NH-C(O)-CH=CH-,其中氮原子与持R1的苯环中的碳原子结合,碳原子与持R2的苯环中的碳原子结合
- R3 选自氢和卤素原子或选自-SO-R5、-SO2-R5、-NH-CO-NH2、-CO-NH2、海因
硫基、C1-4烷基、C1-4烷氧基和-SO2NR5R6 的基团
- R4 选自氢原子、卤素原子和 C1-4 烷基
- R5 是 C1-4 烷基或 C3-8 环烷基
- R6 独立地选自氢原子和 C1-4 烷基
- n、p 和 q 独立地为 0、1、2、3 或 4
- m和s独立地为0、1、2或3
- r 是 0、1 或 2
但条件是
- m 和 r 中至少有一个不为 0
- n+m+p+q+r+s 的总和为 7、8、9、10、11、12 或 13
- q+r+s 的和为 2、3、4、5 或 6
或其药学上可接受的盐、溶液或立体异构体。